Analyst consensus rating
Stoke Therapeutics Analyst Rating: Strong Buy
STOK is rated Strong Buy by 13 analysts with a $46.46 target. As of 2026-08-27.
Direct answer
Stoke Therapeutics's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $46.46.
Forecast evidence checked August 27, 2026.
Get free Stoke Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $33.09
- Average price target
- $46.46
- High price target
- $60.00
- Low price target
- $35.00
- Low target gap
- +5.8%
- Target upside
- +40.4%
- High target gap
- +81.3%
- Target range width
- 75.6%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Stoke Therapeutics?
Stoke Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $46.46.
How far are Stoke Therapeutics's low and high targets from the recorded price?
The low target implies +5.8%, while the high target implies +81.3%.
How many analysts are included in Stoke Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Stoke Therapeutics's target upside or downside calculated?
The average target of $46.46 is divided by the recorded price of $33.09, then one is subtracted to produce +40.4%. This does not guarantee a future return.
When was Stoke Therapeutics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.